Sandoz Group AG (SDZNY)
| Market Cap | 20.15B |
| Revenue (ttm) | 10.11B |
| Net Income (ttm) | -8.00M |
| Shares Out | n/a |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 0.38 (0.86%) |
| Ex-Dividend Date | May 3, 2024 |
| Volume | 702 |
| Average Volume | 33,585 |
| Open | 45.95 |
| Previous Close | 45.94 |
| Day's Range | 45.95 - 46.23 |
| 52-Week Range | 27.79 - 46.80 |
| Beta | n/a |
| RSI | 70.77 |
| Earnings Date | Mar 5, 2025 |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]
Full Company ProfileFinancial Performance
In 2023, Sandoz Group AG's revenue was $9.98 billion, an increase of 7.23% compared to the previous year's $9.31 billion. Earnings were $77.00 million, a decrease of -90.92%.
Financial StatementsNews
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference
MEDIA RELEASE Strong first year as standalone company; global leader Sandoz uniquely positioned in attractive and growing USD 200 billion market for generics and biosimilars Leading in home market Eur...
Intra-Cellular Therapies Stock Soars 19% After Securing Major Patent Victory Over Sandoz
Intra-Cellular Therapies Stock Soars 19% After Securing Major Patent Victory Over Sandoz
Intra-Cellular settles Caplyta patent dispute with Sandoz
Intra-Cellular Therapies (ITCI) stock jumps as the company settles a patent dispute with Sandoz (SDZNY) over Caplyta. Read more here.
Intra-Cellular Therapies Inc (ITCI) Announces Settlement with Sandoz Over CAPLYTA Patent Litigation
Intra-Cellular Therapies Inc (ITCI) Announces Settlement with Sandoz Over CAPLYTA Patent Litigation
Caplin Point gets USFDA approval for eye drops – Difluprednate Ophthalmic Emulsion
Caplin Point Laboratories announced receiving final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05...
Sandoz Charts Path to Swift Generic Ozempic Launch in Canada
Sandoz Group AG plans to use the Canadian market as a trial balloon for generic Ozempic, challenging Novo Nordisk A/S with a copycat version as soon as 2026.
Sandoz Charts Path to Swift Generic Ozempic Launch in Canada
Sandoz Group AG plans to use the Canadian market as a trial balloon for generic Ozempic, challenging Novo Nordisk A/S with a copycat version as soon as 2026.
Glenmark Pharmaceuticals shares in focus as company launches Travoprost Ophthalmic Solution in U.S.
Glenmark Pharmaceuticals Inc., USA, headquartered in Mahwah, New Jersey, has announced the launch of Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution), marking a significant additio...
Glenmark Pharmaceuticals USA launches Travoprost Ophthalmic Solution USP
Glenmark Pharmaceuticals Inc., USA, headquartered in Mahwah, New Jersey, has announced the launch of Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution). This product is a bioequivale...
Agomab Announces the Appointment of Former Sandoz CFO Colin Bond to its Board of Directors
ANTWERP, Belgium--(BUSINESS WIRE)--Agomab Therapeutics NV (‘Agomab') today announced the appointment of Colin Bond to the company's Board of Directors as a non-executive Director and Chairman of the A...
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
MEDIA RELEASE Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD) One of several biosimilar value drivers for Sandoz Sandoz ...
Sandoz reports third-quarter and nine-month 2024 sales
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong third-quarter biosimilars growth of 37% in constant currencies from existing portfolio and recent launches...
Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio
MEDIA RELEASE First FDA-approved abbreviated new drug application (ANDA) to reference medicine Single-dose 100 mg vial for intravenous use, approved for metastatic breast cancer Launch expected to be ...
Sandoz Canada achieves carbon neutral certification for its commercial operations
BOUCHERVILLE, Quebec, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Sandoz Canada obtained carbon neutral certification from the engineering consulting firm LCL Engineering, Environment & Sustainable Development ...
Sandoz Group: Moving To A 'Hold' After A 50% Move
Sandoz Group's stock has surged nearly 50% since my last article, driven by strong performance in the generics and biosimilars sector. Read more here.
Axsome Therapeutics reaches agreement to dismiss patent litigation with Sandoz
Axsome Therapeutics reaches agreement to dismiss patent litigation with Sandoz
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Enzeevu™ (aflibercept-abzv) approved to treat neovascular age-related macular degeneration Further enhances leading US ophthalm...
Sandoz Group AG (SDZNY) (Q2 2024) Earnings Call Transcript Highlights: Strong Biosimilars ...
Sandoz Group AG (SDZNY) (Q2 2024) Earnings Call Transcript Highlights: Strong Biosimilars Growth and Raised Sales Guidance
Half Year 2024 Sandoz Group AG Earnings Call Transcript
Half Year 2024 Sandoz Group AG Earnings Call Transcript